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Abstract 
Purpose: Evidences have shown that neutrophil-to-lymphocyte ratio (NLR) has a prognostic value in patients with 
cancer. We wanted to test the prognostic significance of NLR in prostatic cancer of patients who are candidate to radi-
cal prostatectomy.
Methods: We have considered 731 patients. Complete demographic data including age, tumor stage, Gleason score, 
complete blood count and serum biochemical profile were collected. Pre-treatment percentage of neutrophils and 
NLR were considered, and correlated with patients data and recurrence free survival.
Results: 389 patients were evaluated, mean age 65 years, mean follow-up 51.5 months, mean recurrence free sur-
vival 51.3 months. Total neutrophil count does not correlate with biochemical recurrence and disease free survival. 
Patients with a value higher of 60% of neutrophils are more likely to have a recurrence. Patients with a total lympho-
cyte count <1,500 have a higher rate of relapse. NLR was not correlated with baseline total PSA, with Gleason score 
and with pathological stage; patients with a NLR >3 has a higher incidence of recurrence. In multivariate analysis 
including age, total PSA and NLR, NLR is the most important factor able to predict recurrence. There are some limita-
tions to this study; first, this is a retrospective study, and the total number of patients analyzed is relatively small.
Conclusions: Our study suggests that pre-treatment NLR may be associated with disease free survival in patients 
with prostate cancer, and could be introduced in clinical practice. NLR has the advantage of low economic cost and 
wide availability.
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Background
Inflammation is a critical component in the pathogenesis 
of cancer. It is also important in the progression of cancer 
(Pinato et al. 2014).
The excess of pro-inflammatory cytokines in the organ-
ism of a cancer patient commonly leads to an acute phase 
reaction that reflects both the disease activity as well 
as the host’s innate response towards the tumor. So far, 
the prognostic significance of systemic inflammatory 
reaction in solid tumors as a potential marker of clini-
cal outcome, has been relatively ignored. However, the 
relationship between inflammation and cancer has been 
explored extensively both in animal models and clinical 
trials in the past years (Li et al. 2014).
In cancer patients lymphopenia is the surrogate of an 
impaired cell-mediate immunity, while neutrophilia is 
acknowledged as a response to systematic inflammation 
(Grivennikov et  al. 2010). Neutrophil-to-lymphocyte 
ratio (NLR) is suggested as a marker for general immune 
response to various stress stimuli. NLR was described 
to be correlated with the severity of clinical progress in 
severely ill patients in the intensive care unit (Zahorec 
2001); emerging evidences have shown that NLR has a 
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prognostic value in patients with solid tumors (McMil-
lan 2009); pretreatment high neutrophil count has been 
reported as a poor prognostic factor for survival in 
patients with renal cell carcinoma (Négrier et  al. 2002), 
metastatic melanoma (Schmidt et al. 2005), and advanced 
non-small-cell lung cancer (Teramukai et  al. 2009); in 
addition to be a prognostic score in patients with can-
cer (Proctor et al. 2011; Wei et al. 2014; Rossi et al. 2015; 
Pinato et al. 2012), NLR was found to be an helpful tool 
in the prediction of response to treatment (Edge et  al. 
2010).
The aim of this study is therefore to test the prognostic 
significance of the pre-operative NLR in prostatic cancer 
of patients who are candidate to radical prostatectomy 
(RP) and to evaluate whether this parameter provides 
additional prognostic information to well-established 
clinic and pathological parameters, in particular predict-
ing the biochemical recurrence and disease free survival.
Methods
We retrospectively analyzed patients that underwent rad-
ical prostatectomy registered in a large database. Among 
731 patients operated at our Institution between 2005 
and 2011 for clinically localized prostate cancer, we con-
sidered only patients who did not receive neo-adjuvant 
therapy or did not undergo adjuvant therapy (both hor-
mones or radiation); also patients with factors that may 
influence the NLR such as steroids, chronic lymphatic 
leukemia, infection or other acute events during the 
month before the NLR measurements were excluded.
All the patients underwent open radical prostatectomy 
and extended pelvic lymph nodes dissection, including 
external, internal and obturatory lymph nodes.
Complete demographic data including age, tumor 
stage, Gleason score at biopsy and at final pathological 
examination, surgical margin status (positive vs negative) 
were collected, together with the complete blood count 
and serum biochemical profile. All the clinic and patho-
logic data were retrieved from the database.
TNM classification was according to 2010 TNM sys-
tem (Pinato et  al. 2012). The laboratory data, including 
neutrophil and lymphocyte count, were obtained from 
before the prostate biopsy and 1  day before surgical 
intervention.
Neutrophil-to-lymphocyte ratio was calculated by 
dividing the absolute neutrophil count by the absolute 
lymphocyte count. Potential factors associated with out-
come were evaluated including age, total PSA, Gleason 
score in the RP specimen, pathological stage, neutro-
philia and NLR. Pre-treatment percentage of neutrophils 
and NLR were considered. The value of NLR that best 
discriminated between good and poor outcome, which 
is the most significant p value according to the long-rank 
test, was determined by testing all possible cutoffs.
Follow-up visits after a radical prostatectomy were usu-
ally scheduled shortly after surgery, every 3  months for 
2 years, then every 6 months up to 5 years, and annually 
thereafter; follow-up examination included digital rectal 
examination (DRE) and PSA; radiological investigations 
(abdominal or thoracic CT and/or RMN and/or PET, 
Positron Emission Tomography, scan and/or bone scan) 
were performed in case of rising PSA (Moul 2000) or 
when clinically required; disease recurrence was defined 
as evidence of measurable disease on imaging, including 
CT, MR imaging, PET scan, bone scan or ultrasound, and 
cytological/histological evaluation of suspected lesions.
Statistical analysis
Pearson Chi-square test was used to assess any associa-
tion between categorical variables. Univariate analysis of 
the different clinical factors associated with survival was 
carried out using Kaplan–Meier statistics and log-rank 
test. Each factor was tested for its independent prognos-
tic value using multivariate analysis according to Cox 
proportional hazard model using SPSS statistical package 
version 19 (IBM SPSS Inc., USA).
Ethics statement
All the patients included in this study had given explicit 
written consent for their information to be stored in 
the hospital database and used for research. All clinical 
investigations were conducted according to the principles 
expressed in the Declaration of Helsinki. The Institutional 
Review Board of the Azienda Ospedaliero-Universitaria 
Ospedali Riuniti of Ancona approved the study design.
Results
Of the 731 patients, 389 patients met the inclusion cri-
teria and were considered for the study purpose and 
included in the NLR analysis; mean patients age was 
65  years (range 42–77), with a mean follow-up time of 
51.5  months (range 9–108). Mean recurrence free sur-
vival was 51.3  months (range 9–108) (Additional file  1: 
Table S1).
We have found a statistically significant correlation 
(p < 0.01) between Gleason score and biochemical failure.
Median neutrophil count was 3,670 mm3, median lym-
phocyte count was 1,510 mm3 and median NLR was 2.4.
We have considered the total neutrophil count and we 
have found that it has not a statistically significant cor-
relation with biochemical recurrence and disease free 
survival. Considering then the percentage of neutrophils 
in the leukocyte formula, we have observed that a cut-off 
value of 60% is able to discriminate patients; in fact those 
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having an higher value are more likely to have a recur-
rence (p < 0.05) than those with a lower value (Figure 1); 
by linear regression analysis however this parameter is 
less powerful than baseline PSA and Gleason score to 
predict recurrence.
We have then considered total lymphocyte count, and 
we have found that patients with <1,500 have a higher 
rate of relapse, compared to those with >1,500  mm3 
(Figure 2); we were not able to find a cut-off value of lym-
phocyte percentage of the leukocyte formula able to pre-
dict recurrence.
Finally we have considered NLR ratio; when NLR was 
analyzed as a dichotomous variable, a cut-point of three 
provided the strongest prognostic value in our data set, 
therefore this level was chosen for further studies.
NLR was not correlated with baseline total PSA, with 
Gleason score and with pathological stage; but we have 
found that patients with a NLR >3 has a higher incidence 
of recurrence than patients with a NLR <3 (Figure 3).
Multivariate analysis was conducted, primarily, on 
three factors that can be easily collected at the first con-
sultation in the outpatient clinic of patients with prostate 
cancer: age, total PSA and NLR; NLR is the most impor-
tant factor able to predict recurrence (p  <  0.05) (Addi-
tional file 2: Table S2).
In the multivariate analysis, considering total neutro-
phil and lymphocyte count, NLR, age, total PSA, Gleason 
grading, stage, and surgical margin status, the latter two 
parameters resulted to be the most important factor pre-
dictive of recurrence (Additional file 3: Table S3).
Discussion
Prostate cancer is a common malignancy and a leading 
cause of cancer-related death. Although the long natu-
ral history of this disease usually allows several levels 
of therapeutic intervention, most patients who have 
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Figure 1 Recurrence free survival in patient with percentage of 
neutrophils lower than 60% (0) and higher than 60% (1).
Figure 2 Recurrence free survival in patient with total lymphocyte 
count >1,500 mm3 (0) and <1,500 mm3 (1).
Figure 3 Recurrence free survival in patients with NLR <3 (0) and >3 
(1).
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recurrent disease following initial definitive treatment 
(~1/3 of all patients diagnosed) will ultimately develop 
castrate-resistant disease, the lethal form of the disease.
Active immunotherapy or anti-cancer vaccination are 
treatment approaches currently investigated, a strategy 
designed to elicit and/or augment anti-tumor immune 
responses. Prostate cancer has proven to be particularly 
sensible to immunotherapeutic intervention, given the 
possibility of antigen loss variants as a means for tumors 
to evade immune detection (Olson et al. 2013).
There is strong linkage between inflammation and 
cancer; cancer related inflammation reduces antitumor 
immunity by recruiting regulatory T cells and activating 
chemokines, which results in tumor growth and metas-
tasis. The mechanism between cancer, neutrophilia and 
leukocytosis remains unclear; however, cancer has been 
shown to produce granulocyte colony-stimulating factors 
(Feng et al. 2013). An enhanced neutrophil response and/
or suppression of lymphocytes leading to a high NLR 
might promote carcinogenesis and inhibit antitumor 
immune response. Molecular signaling and inflammatory 
mediators triggered pathways could promote cancer cell 
proliferation, angiogenesis and metastasis (Gueron et al. 
2012). Inflammatory cells have powerful effects on tumor 
development. Early in the neoplastic process, these cells 
produce an attractive environment for tumor growth, 
facilitating genomic instability and promoting angiogen-
esis; but inflammatory response is anti-tumor (Coussens 
and Werb 2002).
Nowadays, tumor stage and other clinical parameters 
such as PSA and Gleason score are used to obtain prog-
nostic information and could be helpful choosing appro-
priate treatment strategies for patients with prostate 
cancer. Peripheral blood tests before treatment or at the 
time of diagnosis may reflect inflammatory conditions 
within the tumor. NLR calculated from a convenient and 
cheap test could provide appropriate prognostic informa-
tion for the patients in the treatment of prostate cancer 
(Wei et al. 2014).
The present study suggests that pre-treatment NLR 
may be associated with progression free survival in 
patients with prostate cancer.
Patients with neutrophil percentage higher than 60%, 
with total lymphocyte count lower than 1,500 mm3 and 
with NLR higher than three showed a higher incidence 
of recurrence; these observations, together with age and 
total PSA, are able to predict recurrence in our patient 
population. These markers have the advantage of low 
economic cost and wide availability.
Patients with pre-treatment NLR <3 had a longer pro-
gression free survival; our observation suggests that 
exploring the combined impact of neutrophil and lym-
phocyte counts may provide prognostic informations.
The association between NLR and outcome is complex 
and remains to be elucidated. A high NLR reflects both 
a heightened neutrophil-dependent inflammatory reac-
tion and a decreased lymphocyte mediated anti-tumor 
immune response, that contribute to aggressive tumor 
biology, cancer progression and poor prognosis (Keiz-
man et al. 2012; Ohno et al. 2010; An et al. 2010). It has 
been observed that the neutrophil count alone may not 
reflect the prognostic informations of a decreased lym-
phocyte mediated immune response, and a low lympho-
cyte count alone may not reflect the neutrophil driven 
tumorigenesis process (18); thus the NLR may reflect the 
combined prognostic information of these processes, and 
be a stronger predictor of anti-tumor immune response 
and patients outcome.
There are some limitations to this study; first, this is a 
retrospective study, which is susceptible to bias in data 
selection and analysis; the total number of patients ana-
lyzed is relatively small and included patients who were 
treated by radical prostatectomy. It was not possible 
to include in this study patients who were not treated 
by surgery, but by hormones or radiotherapy, because 
data would have been altered; furthermore, NLR differs 
among individuals and can be influenced by concurrent 
infection and drugs.
Despite these limitations, our study suggests that 
pre-treatment NLR may be associated with disease free 
survival in patients with prostate cancer, and could be 
introduced in clinical practice. We have also found that 
NLR associated with baseline PSA is a strong predictor of 
recurrence free survival and should be taken into consid-
eration when planning treatment for prostate cancer, in 
particular adjuvant therapy after RP or more aggressive 
therapy in patients who are not candidates for surgery. 
NLR has the advantage of low economic cost and wide 
availability. The results of our study encourage routinely 
monitoring of NLR to predict recurrence in prostate can-
cer patients.
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